Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
Autor: | Christoph Rosak, Gabriele Mertes |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2012 |
Předmět: |
Pharmacology
medicine.medical_specialty business.industry Treatment options Type 2 diabetes Review prediabetes medicine.disease Treatment efficacy side effects Chronic disease Tolerability patient considerations Internal Medicine medicine Prediabetes type 2 diabetes Diabetic patient Intensive care medicine business acarbose Acarbose medicine.drug |
Zdroj: | Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy |
ISSN: | 1178-7007 |
Popis: | The alpha-glucosidase inhibitor acarbose has been used for more than 20 years in the management of hyperglycemia. Owing to its unique mode of action in the gastrointestinal tract, its properties are very different from other antidiabetic medications. Patients on long-term treatment to control a chronic disease are not only interested in good treatment efficacy, but are also even more interested in the safety and side effects of their medications. Significant aspects of acarbose predominantly regarding safety and tolerability in the management of type 2 diabetes and prediabetes are reviewed. It is concluded that acarbose is a convenient long-term treatment option, with benefits for both type 2 diabetics and patients in a prediabetic state. |
Databáze: | OpenAIRE |
Externí odkaz: |